Skip to main content

Liewei Wang

From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.

FY2026 NIH rank #3,932
  • Rising Star
  • Program Leader
  • R01 Holder
  • Early Career
  • Mentor
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 8822085Search this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$4.1M
Full award amounts, FY2026
Award Records
5
Records listing this PI
Award-Linked Rank
#3,932
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Liewei Wang. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

NCI

National Cancer Institute

$1.5M

3 awards · administering

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Liewei Wang as a PI. Multi-PI records show the full award amount for context.

  • 1P50CA298941-01A1P50Contact PI
    Mayo Clinic / University of Minnesota Prostate SPORE
    $2.2M
    award amount
  • 5R01CA288753-02R01Co-investigator
    Ovcoming PARP Inhibitor Resistance
    $633.7K
    award amount
  • 5R01CA285439-02R01Contact PI
    Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC
    $463.5K
    award amount
  • 5R01CA271486-05R01Contact PI
    Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis
    $414K
    award amount
  • 5T32GM008685-29T32Contact PI
    Training Grant in Clinical Pharmacology
    $335.3K
    award amount

Award organization

Organizations that administered FY2026 awards listing Liewei Wang as a PI.

FY2026 award administered by Mayo Clinic (AZ).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Mayo Clinic
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding
  5. 2025
    Entered Top 50% Nationally
    Ranked #7452
  6. 2025
    R01 Grant Holder
  7. 2025
    Program/Center Grant Leader
  8. 2026
    $5M Cumulative Funding
  9. 2026
    Entered Top 25% Nationally
    Ranked #3932